Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15025742,t((1/2)),"Trimethoprim raised the AUC(0, infinity ) and C(max) of repaglinide by 61% (range, 30-117%; P= 0.0008) and 41% (P = 0.005), respectively, and prolonged the t((1/2)) of repaglinide from 0.9 to 1.1 h (P = 0.001).",The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025742/),h,0.9,9234,DB00912,Repaglinide
,15025742,t((1/2)),"Trimethoprim raised the AUC(0, infinity ) and C(max) of repaglinide by 61% (range, 30-117%; P= 0.0008) and 41% (P = 0.005), respectively, and prolonged the t((1/2)) of repaglinide from 0.9 to 1.1 h (P = 0.001).",The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025742/),h,1.1,9235,DB00912,Repaglinide
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),nM,0.0676,17157,DB00912,Repaglinide
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,14.2,17158,DB00912,Repaglinide
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,5.48,17159,DB00912,Repaglinide
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),,0.,17160,DB00912,Repaglinide
,18342586,flow rate,"All analytes including the internal standard (Repaglinide) were chromatographed on reverse phase C(18) column (50 mm x 4.6mm i.d., 5 microm) using acetonitrile: 2mM ammonium acetate buffer, pH 3.4 (90:10, v/v) as mobile phase at a flow rate 0.4 ml/min in an isocratic mode.","Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),[ml] / [min],0.4,20739,DB00912,Repaglinide
>,18342586,recoveries,The recoveries from spiked control samples were >79% for all analytes and internal standard.,"Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),%,79,20740,DB00912,Repaglinide
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],72.4,21994,DB00912,Repaglinide
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],97.2,21995,DB00912,Repaglinide
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],105.9,21996,DB00912,Repaglinide
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],38.5,21997,DB00912,Repaglinide
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],50.3,21998,DB00912,Repaglinide
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],60.3,21999,DB00912,Repaglinide
,31187938,droplet size,"The mean droplet size, zeta potential, and entrapment efficiency of RPG-NEs were 86.5 ± 3.4 nm, -33.8 ± 2.1 mV, and 96.3 ± 2.3%, respectively.","Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),nm,86.5,28820,DB00912,Repaglinide
,31187938,zeta potential,"The mean droplet size, zeta potential, and entrapment efficiency of RPG-NEs were 86.5 ± 3.4 nm, -33.8 ± 2.1 mV, and 96.3 ± 2.3%, respectively.","Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),m,-,28821,DB00912,Repaglinide
,31187938,zeta potential,"The mean droplet size, zeta potential, and entrapment efficiency of RPG-NEs were 86.5 ± 3.4 nm, -33.8 ± 2.1 mV, and 96.3 ± 2.3%, respectively.","Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),m,33.8,28822,DB00912,Repaglinide
,31187938,entrapment efficiency,"The mean droplet size, zeta potential, and entrapment efficiency of RPG-NEs were 86.5 ± 3.4 nm, -33.8 ± 2.1 mV, and 96.3 ± 2.3%, respectively.","Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),m,33.8,28823,DB00912,Repaglinide
,31187938,entrapment efficiency,"The mean droplet size, zeta potential, and entrapment efficiency of RPG-NEs were 86.5 ± 3.4 nm, -33.8 ± 2.1 mV, and 96.3 ± 2.3%, respectively.","Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),%,96.3,28824,DB00912,Repaglinide
,31187938,droplet size,The chitosan-coated RPG-NEs (Cs-RPG-NEs) showed an average droplet size of 149.3 ± 3.9 nm and a positive zeta-potential of +31.5 ± 2.8 mV.,"Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),,149.3,28825,DB00912,Repaglinide
,31187938,zeta-potential,The chitosan-coated RPG-NEs (Cs-RPG-NEs) showed an average droplet size of 149.3 ± 3.9 nm and a positive zeta-potential of +31.5 ± 2.8 mV.,"Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31187938/),mv,31.5,28826,DB00912,Repaglinide
,23776402,50% inhibition concentration(IC50),Fluvastatin inhibited CYP3A4 activity in a concentration-dependent manner with a 50% inhibition concentration(IC50) of 4.1 µM and P-gp activity.,Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23776402/),μM,4.1,30335,DB00912,Repaglinide
,14534525,area under the plasma repaglinide concentration-time curve from time 0 to infinity [AUC(0- infinity )],"In the 3 genotypic groups, the mean +/- SD area under the plasma repaglinide concentration-time curve from time 0 to infinity [AUC(0- infinity )] was 5.8 +/- 2.5 ng.",Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534525/),ng,5.8,32072,DB00912,Repaglinide
,24623479,CLuptake,"Estimated repaglinide CLuptake corresponded to 217 and 113 μL/min/10(6) cells for SLCO1B1 c.521TT/TC and CC, respectively.",Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24623479/),[min·μl] / [10(6)·cells],217,32378,DB00912,Repaglinide
,24623479,CLuptake,"Estimated repaglinide CLuptake corresponded to 217 and 113 μL/min/10(6) cells for SLCO1B1 c.521TT/TC and CC, respectively.",Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24623479/),[min·μl] / [10(6)·cells],113,32379,DB00912,Repaglinide
,9877000,relative bioavailability,"The relative bioavailability of repaglinide (AUC(tablet)/AUC(oral solution)) was 110% (95% CI, 103%-117%).","Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877000/),%,110,32962,DB00912,Repaglinide
,9877000,absolute bioavailability,"In study 2 the absolute bioavailability of repaglinide administered as a tablet was 62.5% (95% CI, 49.2%-79.5%) relative to an intravenous infusion of the same dose.","Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877000/),%,62.5,32963,DB00912,Repaglinide
,16406450,flow rate,The flow rate was set at 0.2 mL/min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),[ml] / [min],0.2,35009,DB00912,Repaglinide
,16406450,time of analysis,Repaglinide was chosen as an internal standard and the time of analysis was 12 min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),min,12,35010,DB00912,Repaglinide
,16406450,extraction recovery,The extraction recovery of SR26334 from plasma was within the range of 85-90%.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),%,85-90,35011,DB00912,Repaglinide
,24697183,half-life,"Repaglinide, an oral antidiabetic agent, has a rapid onset of action and short half-life of approximately 1 h.",Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697183/),h,1,36576,DB00912,Repaglinide
less,26692235,serum half-life,"Given its short serum half-life of less than 1 h, hypoglycemic effects of repaglinide are expected to cease within a few hours post-ingestion.",Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26692235/),h,1,37829,DB00912,Repaglinide
,23792547,zeta potential,The zeta potential was in the range between - 16.48 ± 2.02 and 30.52 ± 3.20 mV.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),mv,- 16.48,46120,DB00912,Repaglinide
,23792547,zeta potential,The zeta potential was in the range between - 16.48 ± 2.02 and 30.52 ± 3.20 mV.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),mv,30.52,46121,DB00912,Repaglinide
,23792547,percentage entrapment efficiency (EE%),The percentage entrapment efficiency (EE%) was 81.4 ± 1.8% to 92.7 ± 1.4%.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),%,81.4,46122,DB00912,Repaglinide
,23792547,percentage entrapment efficiency (EE%),The percentage entrapment efficiency (EE%) was 81.4 ± 1.8% to 92.7 ± 1.4%.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),%,92.7,46123,DB00912,Repaglinide
,23792547,AUC,"Based on in vivo hypoglycemic results, bioavailability parameters like AUC, AUMC, Cmax, Tmax, MRT, t1/2 and relative bioavailability were found to be 2218.88 μIU/mL/h, 381630.3 μIU/mL/h, 41.88 μIU/mL, 36 h, 83.24h, and 52.79 h respectively.",Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),[μiu] / [h·ml],2218.88,46124,DB00912,Repaglinide
,23792547,t1/2,"Based on in vivo hypoglycemic results, bioavailability parameters like AUC, AUMC, Cmax, Tmax, MRT, t1/2 and relative bioavailability were found to be 2218.88 μIU/mL/h, 381630.3 μIU/mL/h, 41.88 μIU/mL, 36 h, 83.24h, and 52.79 h respectively.",Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),h,52.79,46125,DB00912,Repaglinide
,20175819,elimination rate constant (k(el)),"Using the npag program, the mean elimination rate constant (k(el)) of repaglinide was 0.58 +/- 0.27 h and the volume of distribution (V(d)) was 23.09 +/- 9.19 L/h.",Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175819/),h,0.58,55572,DB00912,Repaglinide
,20175819,volume of distribution (V(d)),"Using the npag program, the mean elimination rate constant (k(el)) of repaglinide was 0.58 +/- 0.27 h and the volume of distribution (V(d)) was 23.09 +/- 9.19 L/h.",Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175819/),[l] / [h],23.09,55573,DB00912,Repaglinide
,30633968,IC50,Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM).,"Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,2.9,57230,DB00912,Repaglinide
,30633968,IC50,"The CYP2C8 IC50 of 4.5 μM in RLM for saroglitazar, supported the use of rats for this DDI study.","Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,4.5,57231,DB00912,Repaglinide
,21491451,area under the curves,"The area under the curves after oral administration of optimised RG-SLN formulation and RG control were 113.36 ± 3.01 and 08.08 ± 1.98 h/(ng · mL), respectively.",In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491451/),[h] / [ml·ng],113.36,58684,DB00912,Repaglinide
,21491451,area under the curves,"The area under the curves after oral administration of optimised RG-SLN formulation and RG control were 113.36 ± 3.01 and 08.08 ± 1.98 h/(ng · mL), respectively.",In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491451/),[h] / [ml·ng],08.08,58685,DB00912,Repaglinide
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],758,58897,DB00912,Repaglinide
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],780,58898,DB00912,Repaglinide
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2327,58899,DB00912,Repaglinide
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2148,58900,DB00912,Repaglinide
,24939312,m/z,The ion transitions monitored were m/z 412.8→165.1 for butoconazole and m/z 453.4→230.3 for the internal standard.,Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),,412.8,59918,DB00912,Repaglinide
,24939312,m/z,The ion transitions monitored were m/z 412.8→165.1 for butoconazole and m/z 453.4→230.3 for the internal standard.,Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),,165.1,59919,DB00912,Repaglinide
,24939312,m/z,The ion transitions monitored were m/z 412.8→165.1 for butoconazole and m/z 453.4→230.3 for the internal standard.,Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),,453.4,59920,DB00912,Repaglinide
,24939312,m/z,The ion transitions monitored were m/z 412.8→165.1 for butoconazole and m/z 453.4→230.3 for the internal standard.,Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),,230.3,59921,DB00912,Repaglinide
,24939312,run time,"The chromatographic run time was 3.5 min per injection, with retention time of 2.47 min and 2.15 min for butoconazole and repaglinide, respectively.",Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),[min] / [injection],3.5,59922,DB00912,Repaglinide
,24939312,retention time,"The chromatographic run time was 3.5 min per injection, with retention time of 2.47 min and 2.15 min for butoconazole and repaglinide, respectively.",Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),min,2.47,59923,DB00912,Repaglinide
,24939312,retention time,"The chromatographic run time was 3.5 min per injection, with retention time of 2.47 min and 2.15 min for butoconazole and repaglinide, respectively.",Development of a liquid chromatography-tandem mass spectrometry method for determination of butoconazole nitrate in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939312/),min,2.15,59924,DB00912,Repaglinide
,20923517,bioavailability,Repaglinide (RPG) is an oral hypoglycemic agent with excellent bioavailability (90-98%) and a short plasma half-life (2-6 h).,Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),%,90-98,60198,DB00912,Repaglinide
,20923517,plasma half-life,Repaglinide (RPG) is an oral hypoglycemic agent with excellent bioavailability (90-98%) and a short plasma half-life (2-6 h).,Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),h,2-6,60199,DB00912,Repaglinide
,20923517,particle size,"The mean particle size of the RPGNP1 and RPGNP2 formulations was 387.8 ± 11.9 and 310.2 ± 12.4 nm, respectively, with a zeta potential of -27.4 ± 0.7 and -15.7 ± 0.5 mV, respectively.",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),nm,387.8,60200,DB00912,Repaglinide
,20923517,particle size,"The mean particle size of the RPGNP1 and RPGNP2 formulations was 387.8 ± 11.9 and 310.2 ± 12.4 nm, respectively, with a zeta potential of -27.4 ± 0.7 and -15.7 ± 0.5 mV, respectively.",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),nm,310.2,60201,DB00912,Repaglinide
,20923517,zeta potential,"The mean particle size of the RPGNP1 and RPGNP2 formulations was 387.8 ± 11.9 and 310.2 ± 12.4 nm, respectively, with a zeta potential of -27.4 ± 0.7 and -15.7 ± 0.5 mV, respectively.",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),mv,-,60202,DB00912,Repaglinide
,20923517,zeta potential,"The mean particle size of the RPGNP1 and RPGNP2 formulations was 387.8 ± 11.9 and 310.2 ± 12.4 nm, respectively, with a zeta potential of -27.4 ± 0.7 and -15.7 ± 0.5 mV, respectively.",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),mv,27.4,60203,DB00912,Repaglinide
,20923517,zeta potential,"The mean particle size of the RPGNP1 and RPGNP2 formulations was 387.8 ± 11.9 and 310.2 ± 12.4 nm, respectively, with a zeta potential of -27.4 ± 0.7 and -15.7 ± 0.5 mV, respectively.",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),mv,15.7,60204,DB00912,Repaglinide
,20923517,entrapment efficiency,"The entrapment efficiency and drug content of RPGNP1 (58.7 ± 1.3% and 27.4 ± 2.3%, respectively) was better than that of RPGNP2 (45.8 ± 1.2% and 24.3 ± 1.1%, respectively).",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),%,58.7,60205,DB00912,Repaglinide
,20923517,entrapment efficiency,"The entrapment efficiency and drug content of RPGNP1 (58.7 ± 1.3% and 27.4 ± 2.3%, respectively) was better than that of RPGNP2 (45.8 ± 1.2% and 24.3 ± 1.1%, respectively).",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),%,45.8,60206,DB00912,Repaglinide
,20923517,entrapment efficiency,"The entrapment efficiency and drug content of RPGNP1 (58.7 ± 1.3% and 27.4 ± 2.3%, respectively) was better than that of RPGNP2 (45.8 ± 1.2% and 24.3 ± 1.1%, respectively).",Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923517/),%,24.3,60207,DB00912,Repaglinide
,22865648,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of MFN, RGN and IS occurred at 1.64, 2.21 and 2.15 min, respectively.",LC-MS/MS-ESI method for simultaneous quantitation of metformin and repaglinidie in rat plasma and its application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22865648/),min,3.5,63127,DB00912,Repaglinide
,34071139,IC50,The mean (range) IC50 of QCT on the microsomal metabolism of RPG was estimated to be 16.7 (13.0-18.6) μM in the rat liver microsome (RLM) and 3.0 (1.53-5.44) μM in the human liver microsome (HLM).,Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34071139/),μM,16.7,65717,DB00912,Repaglinide
,34071139,IC50,The mean (range) IC50 of QCT on the microsomal metabolism of RPG was estimated to be 16.7 (13.0-18.6) μM in the rat liver microsome (RLM) and 3.0 (1.53-5.44) μM in the human liver microsome (HLM).,Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34071139/),μM,3.0,65718,DB00912,Repaglinide
,34071139,Ki,The type of inhibition exhibited by QCT on RPG metabolism was determined to be a mixed inhibition with a Ki of 72.0 μM in RLM and 24.2 μM in HLM as obtained through relevant graphical and enzyme inhibition model-based analyses.,Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34071139/),μM,72.0,65719,DB00912,Repaglinide
,34071139,Ki,The type of inhibition exhibited by QCT on RPG metabolism was determined to be a mixed inhibition with a Ki of 72.0 μM in RLM and 24.2 μM in HLM as obtained through relevant graphical and enzyme inhibition model-based analyses.,Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34071139/),μM,24.2,65720,DB00912,Repaglinide
,22210483,IC(50),"Efonidipine inhibited CYP3A4 activity with an IC(50) value of 0.08 μM, and efonidipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),μM,0.08,68078,DB00912,Repaglinide
,22210483,absolute bioavailability,Efonidipine also significantly (P < 0.01 for 3 mg/kg) increased the absolute bioavailability (AB) of repaglinide by 51.5% compared to the oral control group (33.6%).,Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),%,33.6,68079,DB00912,Repaglinide
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,34,76953,DB00912,Repaglinide
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,18,76954,DB00912,Repaglinide
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.64,76955,DB00912,Repaglinide
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.98,76956,DB00912,Repaglinide
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.5,82164,DB00912,Repaglinide
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.1,82165,DB00912,Repaglinide
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.94,82166,DB00912,Repaglinide
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],-,82167,DB00912,Repaglinide
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.23,82168,DB00912,Repaglinide
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00912,Repaglinide
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00912,Repaglinide
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00912,Repaglinide
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00912,Repaglinide
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00912,Repaglinide
,32187961,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[ng] / [ml],70.80,90327,DB00912,Repaglinide
,32187961,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[ng] / [ml],124.71,90328,DB00912,Repaglinide
,32187961,area under the plasma concentration-time curve (AUC),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[h·μg] / [l],134.89,90329,DB00912,Repaglinide
,32187961,area under the plasma concentration-time curve (AUC),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[h·μg] / [l],245.95,90330,DB00912,Repaglinide
,32187961,net efflux ratio,"The transepithelial transport rate of repaglinide from basolateral-to-apical in MDR1-MDCK cells was 3.6-fold higher than the apical-to-basolateral rate with a net efflux ratio of 1.92 compared with mock-MDCK cells, which was significantly decreased following co-administration with genistein or Ver.",Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),,1.92,90331,DB00912,Repaglinide
,24399740,IC50,"Administration of nifedipine resulted in inhibition CYP3A4 activity with an IC50 value of 7.8 μM, and nifedipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),μM,7.8,95337,DB00912,Repaglinide
,24399740,absolute bioavailability (AB),Nifedipine also increased the absolute bioavailability (AB) of repaglinide by 50.0% compared to the oral control group (33.6%).,Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),%,33.6,95338,DB00912,Repaglinide
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.2,96896,DB00912,Repaglinide
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.0,96897,DB00912,Repaglinide
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.6,96898,DB00912,Repaglinide
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.9,96899,DB00912,Repaglinide
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.2,96900,DB00912,Repaglinide
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,3.0,96901,DB00912,Repaglinide
over,16759733,gastric residence time (GRT),Prolonged gastric residence time (GRT) of over 6 h was achieved in all animals for calcium silicate based floating microspheres of Rg.,A novel calcium silicate based microspheres of repaglinide: in vivo investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759733/),h,6,112799,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB00912,Repaglinide
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB00912,Repaglinide
,11112092,Tmax1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),h,0.61,118555,DB00912,Repaglinide
,11112092,Tmax2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),h,1.45,118556,DB00912,Repaglinide
,11112092,Cmax1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),[ng] / [ml],40.60,118557,DB00912,Repaglinide
,11112092,Cmax2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),[ng] / [ml],42.70,118558,DB00912,Repaglinide
,11112092,T1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),h,0.12,118559,DB00912,Repaglinide
,11112092,T2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),h,0.67,118560,DB00912,Repaglinide
,11112092,T3,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1 0.61 +/- 0.14 h, Tmax2 1.45 +/- 0.43 h, Cmax1 40.60 +/- 20.57 ng/ml, Cmax2 42.70 +/- 17.54 ng/ml, T1 0.12 +/- 0.07 h, T2 0.67 +/- 0.30 h and T3 1.03 +/- 0.35 h.",A double-site absorption model fits to pharmacokinetic data of repaglinide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11112092/),h,1.03,118561,DB00912,Repaglinide
,17240100,recovery,The recovery of repaglinide was 92%+/-55.31.,Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),%,92,125550,DB00912,Repaglinide
,17240100,flow rate,The flow rate was 1 ml/min.,Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ml] / [min],1,125551,DB00912,Repaglinide
,17240100,retention time,"The retention time for repaglinide and indomethacin were approximately 6.2 and 5.3 min, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),min,6.2,125552,DB00912,Repaglinide
,17240100,retention time,"The retention time for repaglinide and indomethacin were approximately 6.2 and 5.3 min, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),min,5.3,125553,DB00912,Repaglinide
,17240100,limits of detection,"The limits of detection and quantification were 10 ng/ml and 20 ng/ml, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ng] / [ml],10,125554,DB00912,Repaglinide
,17240100,limits of detection,"The limits of detection and quantification were 10 ng/ml and 20 ng/ml, respectively.",Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240100/),[ng] / [ml],20,125555,DB00912,Repaglinide
,10501822,peak plasma concentration,"After oral dosing, a mean peak plasma concentration of repaglinide of 27.74 ng.","Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501822/),ng,27.74,126881,DB00912,Repaglinide
,10501822,time to peak concentration,ml(-1)) was observed with a time to peak concentration of 0.5 h.,"Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501822/),h,0.5,126882,DB00912,Repaglinide
,24465043,Cmax,The mean (SD) Cmax for repaglinide with the test and reference formulations were 20.0 (5.1) and 18.7 (8.7) ng/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[ng] / [ml],20.0,140190,DB00912,Repaglinide
,24465043,Cmax,The mean (SD) Cmax for repaglinide with the test and reference formulations were 20.0 (5.1) and 18.7 (8.7) ng/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[ng] / [ml],18.7,140191,DB00912,Repaglinide
,24465043,AUC0-t,The AUC0-t for the test formulation was 46.3 (15.1) and AUC0-∞ was 47.9 (16.5) ng(•)h/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),,46.3,140192,DB00912,Repaglinide
,24465043,AUC0-∞,The AUC0-t for the test formulation was 46.3 (15.1) and AUC0-∞ was 47.9 (16.5) ng(•)h/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[)h·ng(] / [ml],47.9,140193,DB00912,Repaglinide
,24465043,Tmax,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.2,140194,DB00912,Repaglinide
,24465043,Tmax,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.5,140195,DB00912,Repaglinide
,24465043,t1/2,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.0,140196,DB00912,Repaglinide
,24465043,t1/2,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,0.9,140197,DB00912,Repaglinide
,19721250,diameter,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),mmpsi,10,149179,DB00912,Repaglinide
,19721250,hardness,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),,60,149180,DB00912,Repaglinide
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,73.6,149181,DB00912,Repaglinide
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,57.2-60.8,149182,DB00912,Repaglinide
,16447051,peak time,"Also the half-life of repaglinide was unaffected, but the median peak time of repaglinide was shortened from 40 min to 20 min by pioglitazone (P=0.014).","Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16447051/),min,40,149586,DB00912,Repaglinide
,16447051,peak time,"Also the half-life of repaglinide was unaffected, but the median peak time of repaglinide was shortened from 40 min to 20 min by pioglitazone (P=0.014).","Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16447051/),min,20,149587,DB00912,Repaglinide
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,5.59,150101,DB00912,Repaglinide
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.34,150102,DB00912,Repaglinide
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.69,150103,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,27,151996,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,80,151997,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),[μM] / [l],16,151998,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,75,151999,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,19.3,152000,DB00912,Repaglinide
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,21.5,152001,DB00912,Repaglinide
,15373931,half-life,The mean half-life of repaglinide was 1.3 h in all phases.,Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373931/),h,1.3,158397,DB00912,Repaglinide
over,17523003,gastric residence time (GRT),Prolonged gastric residence time (GRT) of over 6 hr was achieved in all subjects for calcium silicate based floating granules of Rg.,Porous carrier based floating granular delivery system of repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523003/),h,6,178017,DB00912,Repaglinide
,10199798,T(1/2),The T(1/2) of repaglinide after multiple dosing was 1.7 hours.,Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10199798/),h,1.7,188044,DB00912,Repaglinide
,23311652,half-life,A transdermal delivery system is warranted for repaglinide (RPG) which possesses half-life of 1 h and oral bioavailability of 56%.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),h,1,192741,DB00912,Repaglinide
,23311652,oral bioavailability,A transdermal delivery system is warranted for repaglinide (RPG) which possesses half-life of 1 h and oral bioavailability of 56%.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),%,56,192742,DB00912,Repaglinide
,23311652,entrapment efficiency,RPG ethosomes possessing the size of 0.171-1.727 µm and entrapment efficiency of 75-92% were obtained.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),%,75-92,192743,DB00912,Repaglinide
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,1.3,210928,DB00912,Repaglinide
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,3.7,210929,DB00912,Repaglinide
,12687332,t(1/2),"Although itraconazole alone raised repaglinide AUC only 1.4-fold (1.1- to 1.9-fold; p<0.001), the gemfibrozil-itraconazole combination raised it 19.4-fold (12.9- to 24.7-fold) and prolonged the t(1/2) of repaglinide to 6.1 h (p<0.001).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,6.1,210930,DB00912,Repaglinide
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,15.8,213950,DB00912,Repaglinide
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,11.6,213951,DB00912,Repaglinide
,31729898,encapsulation efficiency (EE),"The particles size, encapsulation efficiency (EE), drug loading (DL) of REP-NLCs-Small and REP-NLCs-Large size preparations were about 79 nm and 325 nm, 96.83% and 98.60%, 4.41% and 3.05%, respectively.","Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729898/),,96,214019,DB00912,Repaglinide
,31729898,encapsulation efficiency (EE),"The particles size, encapsulation efficiency (EE), drug loading (DL) of REP-NLCs-Small and REP-NLCs-Large size preparations were about 79 nm and 325 nm, 96.83% and 98.60%, 4.41% and 3.05%, respectively.","Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729898/),%,4.41,214020,DB00912,Repaglinide
,31729898,drug loading (DL),"The particles size, encapsulation efficiency (EE), drug loading (DL) of REP-NLCs-Small and REP-NLCs-Large size preparations were about 79 nm and 325 nm, 96.83% and 98.60%, 4.41% and 3.05%, respectively.","Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation, characterization, pharmacokinetics, and in situ intestinal perfusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729898/),%,3.05,214021,DB00912,Repaglinide
,31363741,m/z,Ion transitions at m/z 168.0→132.1 for chlorzoxazone and m/z 451.3→379.3 for repaglinide (internal standard) were used for the LC-MS/MS analysis.,An LC-MS/MS Validated Method for Quantification of Chlorzoxazone in Human Plasma and Its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363741/),,168.0,215869,DB00912,Repaglinide
,31363741,m/z,Ion transitions at m/z 168.0→132.1 for chlorzoxazone and m/z 451.3→379.3 for repaglinide (internal standard) were used for the LC-MS/MS analysis.,An LC-MS/MS Validated Method for Quantification of Chlorzoxazone in Human Plasma and Its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363741/),,132.1,215870,DB00912,Repaglinide
,31363741,m/z,Ion transitions at m/z 168.0→132.1 for chlorzoxazone and m/z 451.3→379.3 for repaglinide (internal standard) were used for the LC-MS/MS analysis.,An LC-MS/MS Validated Method for Quantification of Chlorzoxazone in Human Plasma and Its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363741/),,451.3,215871,DB00912,Repaglinide
,31363741,m/z,Ion transitions at m/z 168.0→132.1 for chlorzoxazone and m/z 451.3→379.3 for repaglinide (internal standard) were used for the LC-MS/MS analysis.,An LC-MS/MS Validated Method for Quantification of Chlorzoxazone in Human Plasma and Its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31363741/),,379.3,215872,DB00912,Repaglinide
,24783509,m,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,453.3,221398,DB00912,Repaglinide
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,447.2,221399,DB00912,Repaglinide
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,327.4,221400,DB00912,Repaglinide
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,285.1,221401,DB00912,Repaglinide
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,192.9,221402,DB00912,Repaglinide
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],35,229421,DB00912,Repaglinide
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],7.5,229422,DB00912,Repaglinide
,14748619,bioavailability,"The pharmacokinetics of nateglinide are characterised by rapid absorption and elimination, with good (73%) bioavailability.","Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748619/),%,73,236941,DB00912,Repaglinide
,18388877,half-life,"The peak repaglinide concentration increased approximately twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.",The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18388877/),h,1.2,237169,DB00912,Repaglinide
,18388877,half-life,"The peak repaglinide concentration increased approximately twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.",The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18388877/),h,2-3,237170,DB00912,Repaglinide
,1770103,limit of detection,The limit of detection was 5 ng/ml in plasma.,Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770103/),[ng] / [ml],5,239785,DB00912,Repaglinide
,19773535,turnover half-life,"Based on the recovery of repaglinide oral clearance, the in vivo turnover half-life of CYP2C8 was estimated to average 22 +/- 6 h (mean +/- S.D.).",CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773535/),h,22,240272,DB00912,Repaglinide
,16198658,IC50,"In vitro, cyclosporine inhibited the formation of M1 (IC50 [concentration of inhibitor to cause 50% inhibition of original enzyme activity], 0.2 micromol/L) and M2 (IC50, 4.3 micromol/L) but had no effect on M4.",Cyclosporine markedly raises the plasma concentrations of repaglinide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198658/),[μM] / [l],0.2,241315,DB00912,Repaglinide
,16198658,IC50,"In vitro, cyclosporine inhibited the formation of M1 (IC50 [concentration of inhibitor to cause 50% inhibition of original enzyme activity], 0.2 micromol/L) and M2 (IC50, 4.3 micromol/L) but had no effect on M4.",Cyclosporine markedly raises the plasma concentrations of repaglinide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198658/),[μM] / [l],4.3,241316,DB00912,Repaglinide
,28115226,half-life,"Repaglinide, an oral antidiabetic agent, has a rapid onset of action and short half-life of approximately 1h.",Dual crosslinked pectin-alginate network as sustained release hydrophilic matrix for repaglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115226/),h,1,241497,DB00912,Repaglinide
,28115226,particle size,The particle size of beads was in the range of 698±2.34-769±1.43μm.,Dual crosslinked pectin-alginate network as sustained release hydrophilic matrix for repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115226/),μm,698,241498,DB00912,Repaglinide
,28115226,particle size,The particle size of beads was in the range of 698±2.34-769±1.43μm.,Dual crosslinked pectin-alginate network as sustained release hydrophilic matrix for repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115226/),μm,769,241499,DB00912,Repaglinide
,28115226,drug entrapment efficiency,The drug entrapment efficiency varied between 55.24±4.61 to 82.29±3.42%.,Dual crosslinked pectin-alginate network as sustained release hydrophilic matrix for repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115226/),%,55.24,241500,DB00912,Repaglinide
,28115226,drug entrapment efficiency,The drug entrapment efficiency varied between 55.24±4.61 to 82.29±3.42%.,Dual crosslinked pectin-alginate network as sustained release hydrophilic matrix for repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115226/),%,82.29,241501,DB00912,Repaglinide
,11452245,elimination half-life,The mean elimination half-life of repaglinide was prolonged from 1.4 to 1.7 hours (P <.05) by clarithromycin.,The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452245/),h,1.4,244247,DB00912,Repaglinide
,11452245,elimination half-life,The mean elimination half-life of repaglinide was prolonged from 1.4 to 1.7 hours (P <.05) by clarithromycin.,The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452245/),h,1.7,244248,DB00912,Repaglinide
,30003863,size,"RPG nanoparticles size, polydispersity index (PDI) and zeta potential were found to be 280.8 ± 15 nm, 0.279 ± 0.04 and - 25.81 ± 1.6mV, respectively.","Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30003863/),nm,280.8,249195,DB00912,Repaglinide
,30003863,polydispersity index (PDI),"RPG nanoparticles size, polydispersity index (PDI) and zeta potential were found to be 280.8 ± 15 nm, 0.279 ± 0.04 and - 25.81 ± 1.6mV, respectively.","Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30003863/),mv,0.279,249196,DB00912,Repaglinide
,30003863,zeta potential,"RPG nanoparticles size, polydispersity index (PDI) and zeta potential were found to be 280.8 ± 15 nm, 0.279 ± 0.04 and - 25.81 ± 1.6mV, respectively.","Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30003863/),mv,-,249197,DB00912,Repaglinide
,30003863,zeta potential,"RPG nanoparticles size, polydispersity index (PDI) and zeta potential were found to be 280.8 ± 15 nm, 0.279 ± 0.04 and - 25.81 ± 1.6mV, respectively.","Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30003863/),mv,25.81,249198,DB00912,Repaglinide
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],2.3,255437,DB00912,Repaglinide
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.3,255438,DB00912,Repaglinide
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.15,255439,DB00912,Repaglinide
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],0.8,255440,DB00912,Repaglinide
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB00912,Repaglinide
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,17.8,268318,DB00912,Repaglinide
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,27.7,268319,DB00912,Repaglinide
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,30.8,268320,DB00912,Repaglinide
,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,38.8,268321,DB00912,Repaglinide
>,25264242,IC50,"Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17.8, 27.7, 30.8 and 38.8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50 > 100 µm).",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),µm,100,268322,DB00912,Repaglinide
>,25264242,[I]/Ki ratio,"The results of a static model indicated an [I]/Ki ratio >0.1 for CYP1A2, 2C8, 2C9 and 2C19.",Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,0.1,268323,DB00912,Repaglinide
<,25264242,AUC ratios,Simulation of the area under the plasma concentration-time curve (AUC) of these four CYP substrates in the presence and absence of orteronel revealed geometric mean AUC ratios <1.25.,Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264242/),,1.25,268324,DB00912,Repaglinide
,30962675,tensile strength,"Optimized formula showed satisfactory tensile strength (145.862 g/cm2), rapid disintegration (22.2 seconds), and higher drug release rate (97.799% within 30 minutes).","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[g] / [cm2],145.862,268543,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],296.072,268544,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],116.932,268545,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],164.917,268546,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],56.568,268547,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],95.368,268548,DB00912,Repaglinide
,30962675,bioavailability,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],31.925,268549,DB00912,Repaglinide
,30962675,AUC,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],296.072,268550,DB00912,Repaglinide
,30962675,AUC,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],164.917,268551,DB00912,Repaglinide
,30962675,AUC,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],95.368,268552,DB00912,Repaglinide
,30962675,Cmax,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],296.072,268553,DB00912,Repaglinide
,30962675,Cmax,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],116.932,268554,DB00912,Repaglinide
,30962675,Cmax,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],56.568,268555,DB00912,Repaglinide
,30962675,Cmax,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[h·μg] / [ml],95.368,268556,DB00912,Repaglinide
,30962675,Cmax,"The drug bioavailability was significantly improved in comparison with plain drug and conventional alginate oral films, where the AUC and Cmax values reached 296.072 μg.h/mL and 116.932 μg/mL in comparison with 164.917 μg.h/mL and 56.568 μg/mL for alginate film and 95.368 μg.h/mL and 31.925 μg/mL for plain drug, respectively.","Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),[μg] / [ml],31.925,268557,DB00912,Repaglinide
,30962675,Tmax,Tmax also showed significant reduction to be only 30 minutes in comparison with 60 minutes for other forms.,"Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),min,30,268558,DB00912,Repaglinide
,30962675,Tmax,Tmax also showed significant reduction to be only 30 minutes in comparison with 60 minutes for other forms.,"Hexyl alginate derivative, an amphiphilic innovative buccal film-forming material of promising mechanical and release characteristics for the improvement of repaglinide bioavailability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962675/),min,60,268559,DB00912,Repaglinide
